disulfiram has been researched along with Cirrhosis in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Since, LOX enzymes need copper (Cu) for their proper catalytic activity; the present study investigated the efficacy of a copper chelator, disulfiram (DSF) in renal fibrosis." | 8.12 | Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes. ( Godugu, C; Kaki, VR; Saifi, MA; Shaikh, AS, 2022) |
| "Disulfiram can inhibit inflammation and fibrosis in renal fibrosis rats by inhibiting GSDMD." | 8.02 | Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis. ( Han, X; Zhang, R; Zhang, Y, 2021) |
| " Since, LOX enzymes need copper (Cu) for their proper catalytic activity; the present study investigated the efficacy of a copper chelator, disulfiram (DSF) in renal fibrosis." | 4.12 | Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes. ( Godugu, C; Kaki, VR; Saifi, MA; Shaikh, AS, 2022) |
| "Disulfiram can inhibit inflammation and fibrosis in renal fibrosis rats by inhibiting GSDMD." | 4.02 | Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis. ( Han, X; Zhang, R; Zhang, Y, 2021) |
| "Mechanisms underlying scarring are largely unknown in MMP and effective treatment options are limited." | 1.62 | Increased Fibrosis in a Mouse Model of Anti-Laminin 332 Mucous Membrane Pemphigoid Remains Unaltered by Inhibition of Aldehyde Dehydrogenase. ( Boch, K; Brinckmann, J; Busch, H; Chakievska, L; Diel, L; Fähnrich, A; Künzel, S; Patzelt, S; Pigors, M; Schmidt, E; Steenbock, H, 2021) |
| "Desmoplasia in human pancreatic cancer (PC) promotes cancer progression and hinders effective drug delivery." | 1.43 | Characterization and use of HapT1-derived homologous tumors as a preclinical model to evaluate therapeutic efficacy of drugs against pancreatic tumor desmoplasia. ( Ali, SA; Batra, SK; Chakraborty, S; Das, B; Dash, P; Jain, S; Mohanty, AK; Panda, SK; Senapati, S; Suklabaidya, S; Swaminathan, S, 2016) |
| "These data suggest that progressive scarring in OMMP results from ALDH/RA fibroblast autoregulation, that the ALDH1 subfamily has a central role in immune-mediated ocular mucosal scarring, and that ALDH inhibition with disulfiram is a potential and readily translatable antifibrotic therapy." | 1.43 | Aldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring. ( Abraham, DJ; Ahadome, SD; Calder, VL; Daniels, JT; Dart, JK; Norman, JT; Ponticos, M; Rayapureddi, S; Saban, DR; Saw, VP, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Patzelt, S | 1 |
| Pigors, M | 1 |
| Steenbock, H | 1 |
| Diel, L | 1 |
| Boch, K | 1 |
| Chakievska, L | 1 |
| Künzel, S | 1 |
| Busch, H | 1 |
| Fähnrich, A | 1 |
| Brinckmann, J | 1 |
| Schmidt, E | 1 |
| Saifi, MA | 1 |
| Shaikh, AS | 1 |
| Kaki, VR | 1 |
| Godugu, C | 1 |
| Wang, X | 2 |
| Ye, H | 1 |
| Yang, S | 1 |
| Sha, X | 1 |
| Zhang, T | 1 |
| Chen, R | 1 |
| Xiao, W | 1 |
| Yang, H | 1 |
| Liu, C | 1 |
| Tang, J | 1 |
| Liu, S | 1 |
| Shen, C | 1 |
| Zhou, X | 1 |
| Lu, J | 1 |
| Li, M | 1 |
| Zhu, L | 1 |
| Zhang, Y | 1 |
| Zhang, R | 1 |
| Han, X | 1 |
| Suklabaidya, S | 1 |
| Das, B | 1 |
| Ali, SA | 1 |
| Jain, S | 1 |
| Swaminathan, S | 1 |
| Mohanty, AK | 1 |
| Panda, SK | 1 |
| Dash, P | 1 |
| Chakraborty, S | 1 |
| Batra, SK | 1 |
| Senapati, S | 1 |
| Ahadome, SD | 1 |
| Abraham, DJ | 1 |
| Rayapureddi, S | 1 |
| Saw, VP | 1 |
| Saban, DR | 1 |
| Calder, VL | 1 |
| Norman, JT | 1 |
| Ponticos, M | 1 |
| Daniels, JT | 1 |
| Dart, JK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quantitative Analysis of the Expression of Dementia-relevant Genes by Intake of the Drug Disulfiram[NCT03212599] | 17 participants (Actual) | Observational | 2013-05-31 | Completed | |||
| A Randomized, Double-blind, Placebo-controlled Safety and Clinical Outcomes Study of Disulfiram in Subjects With Moderate COVID-19[NCT04594343] | Phase 2 | 140 participants (Actual) | Interventional | 2020-11-20 | Completed | ||
| A Phase I Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma[NCT04521335] | Phase 1 | 2 participants (Actual) | Interventional | 2021-05-21 | Terminated (stopped due to Closed at PI's Request) | ||
| DISulfiram for COvid-19 (DISCO) Trial: A Phase 2 Double-Blind, Randomized Placebo-Controlled Trial of Disulfiram Compared to Standard Care in Patients With Symptomatic COVID-19[NCT04485130] | Phase 2 | 11 participants (Actual) | Interventional | 2021-08-18 | Terminated (stopped due to Low COVID case numbers, competing COVID treatments available) | ||
| Neurocognitive Mechanisms of Disulfiram Treatment of Alcohol Use Disorder[NCT02735577] | Phase 4 | 7 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The severity of COVID-19 symptoms will be recorded on a 5-point symptom severity scale at each visit for each participant. A question about how much the symptoms bother the participants will be asked. The participant will rank 1 as not at all, 2 as a little bit, 3 as somewhat, 4 as quite a bit and 5 as very much. Higher values represent worse outcomes. Scales are combined to compute a total score at Day 0 and Day 31. A change of the median is reported." (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | units on a scale (Median) |
|---|---|
| Cohort 1: Disulfiram | -2.60 |
| Cohort 1: Placebo | -2.14 |
Change in copies of SARS-CoV-2 PCR virus per mL between Baseline and Day 31. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | copies/mL (Mean) |
|---|---|
| Cohort 1: Disulfiram 1000 mg | -20.89 |
| Cohort 1: Placebo | -20 |
Change in plasma inflammatory biomarker levels (e.g., IL-6, IL-1b) at days 5, 15, and 31. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | fold change (Median) | |
|---|---|---|
| Change in IL-6 (pg/mL) Day 0 to 31 | Change in IL-1B (pg/mL) Day 0 to 31 | |
| Cohort 1: Disulfiram 100 mg | -0.1186 | -0.1402 |
| Cohort 1: Placebo | -0.0215 | 0.0268 |
The safety and tolerability of a 5 day course of disulfiram. The number of adverse events and their grade will be determined for each participant. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AE Grade 3 or Higher | AE Grade 1 or 2 | |
| Cohort 1: Disulfiram 1000 mg | 0 | 4 |
| Cohort 1: Placebo | 1 | 1 |
Number of drinking days (NCT02735577)
Timeframe: 42 days
| Intervention | days (Mean) |
|---|---|
| Disulfiram | 0 |
7 other studies available for disulfiram and Cirrhosis
| Article | Year |
|---|---|
Increased Fibrosis in a Mouse Model of Anti-Laminin 332 Mucous Membrane Pemphigoid Remains Unaltered by Inhibition of Aldehyde Dehydrogenase.
Topics: Aldehyde Dehydrogenase; Animals; Autoimmune Diseases; Cicatrix; Collagen; Disease Models, Animal; Di | 2021 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram Exerts Antifibrotic and Anti-Inflammatory Therapeutic Effects on Perimysial Orbital Fibroblasts in Graves' Orbitopathy.
Topics: Anti-Inflammatory Agents; Cells, Cultured; Disulfiram; Fibroblasts; Fibrosis; Graves Ophthalmopathy; | 2022 |
Cathepsin B/NLRP3/GSDMD axis-mediated macrophage pyroptosis induces inflammation and fibrosis in systemic sclerosis.
Topics: Animals; Caspase 1; Cathepsin B; Disease Models, Animal; Disulfiram; Fibrosis; Humans; Inflammasomes | 2022 |
Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Cell Line; Cell Survival; Disease Models, Animal; Disu | 2021 |
Characterization and use of HapT1-derived homologous tumors as a preclinical model to evaluate therapeutic efficacy of drugs against pancreatic tumor desmoplasia.
Topics: Acetylcysteine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disulfira | 2016 |
Aldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring.
Topics: Adult; Aged; Aged, 80 and over; Aldehyde Dehydrogenase; Animals; Cells, Cultured; Cicatrix; Conjunct | 2016 |